Back

Rationale for the use of xanthine-oxidase inhibitors in patients with increased CV risk

2 November 2023 (17:40 - 18:00)
Organised by: Logo
Seminar Presentation Part of: Metabolic risk factors: new pharmacological strategies? Cardiovascular Pharmacotherapy Open Access EuroCVP 2023 – The annual meeting on advances in cardiovascular pharmacotherapy WG on Cardiovascular Pharmacotherapy

About the speaker

Photo
Professor Claudio Borghi

S. Orsola-Malpighi Policlinic, Bologna (Italy)

2 More presentations in this session

Presentation thumbnail
Management of diabetes and cardiovascular risk in 2023: What’s new?
Professor B. Rocca (Casamassima, IT)
Presentation thumbnail
Pharmacological treatment of obesity: All-in-one
Professor C. Ceconi (Desenzano Del Garda, IT)

Access the full session

Session thumbnail
Metabolic risk factors: new pharmacological strategies?

The Event

Event poster

EuroCVP 2023 – The annual meeting on advances in cardiovascular pharmacotherapy

2 November 2023 17:40 CET
You may be interested in
thumbnail
Congress Presentation
Elevated plasma xanthine oxidoreductase activity predicts cardiovascular events in patients with heart failure with preserved ejection fraction
31 August 2019
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
19 July 2023
thumbnail
Congress Presentation
Cardiovascular safety of non-steroidal anti-inflammatory drug use for gout: A Danish nationwide case-crossover study
27 August 2023
thumbnail
Congress Presentation
Is there value in prescribing colchicine in coronary artery disease for secondary prevention: a meta-analysis of over 5,000 patients
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources